If you run a clinic that administers or dispenses compounded medications, you have almost certainly seen both a "beyond-use date" (BUD) and an "expiration date" on product labels. Many providers assume these terms are interchangeable. They are not — and confusing them can expose your clinic to compliance risk, patient safety issues, and regulatory scrutiny.

This post breaks down exactly what each term means, how they are determined, and why the distinction matters for every licensed clinic working with compounded GLP-1s, peptides, or other sterile preparations.

An expiration date is assigned by a drug manufacturer to a commercially produced, FDA-approved product. It reflects the date through which the manufacturer guarantees the drug's identity, strength, quality, and purity under the labeled storage conditions.

Expiration dates are established through rigorous stability testing conducted over months or years. The manufacturer submits this data to the FDA as part of the drug approval process. The expiration date printed on a commercially manufactured vial of semaglutide, for example, is backed by extensive analytical chemistry data.

Key characteristics of expiration dates:

• Assigned by the original manufacturer
• Based on formal stability studies
• Applies to the unopened, sealed product
• Regulated under 21 CFR Part 211 (Current Good Manufacturing Practice)
• Typically ranges from 12 to 36 months from the date of manufacture

A beyond-use date is assigned by a compounding pharmacy to a preparation it has compounded. It reflects the date or time after which the compounded preparation should not be used.

BUDs are governed primarily by USP Chapter <797> for sterile preparations and USP Chapter <795> for non-sterile preparations. These chapters set maximum BUD limits based on the type of preparation, the sterility category, and the storage conditions.

Key characteristics of BUDs:

• Assigned by the compounding pharmacy
• Based on USP guidelines, not manufacturer stability studies (unless extended BUD testing is performed)
• Applies to the compounded preparation as dispensed
• May be shorter than the expiration date of the raw ingredients used
• Can be extended if the pharmacy conducts and documents appropriate stability testing

Compounding pharmacies do not have the same resources as large pharmaceutical manufacturers to conduct multi-year stability studies on every preparation. USP <797> acknowledges this and sets default BUD limits that are intentionally conservative to protect patient safety.

For example, under USP <797> (2023 revision), the default BUDs for sterile preparations stored under refrigeration are:

• Category 1 (no sterility testing): 12 hours at room temperature, 24 hours refrigerated
• Category 2 (with sterility testing and appropriate controls): Up to 45 days refrigerated for aqueous preparations, depending on conditions

These are defaults. A pharmacy that conducts extended stability testing using validated analytical methods can assign a longer BUD — but only if the data supports it and the testing is properly documented.

Compounded GLP-1 medications — including semaglutide and tirzepatide preparations — are sterile injectables. They fall under USP <797> and are subject to BUD requirements, not expiration date rules.

When your clinic receives a compounded GLP-1 preparation, the label will show a BUD, not an expiration date. That BUD is the pharmacy's determination of how long the preparation remains suitable for use under the labeled storage conditions.

This has practical implications for your clinic:

1. Inventory management: You cannot hold compounded preparations as long as you might hold commercially manufactured drugs. Ordering in quantities that match your patient volume is essential.

2. Storage compliance: The BUD is only valid if the preparation is stored as labeled. A refrigerated preparation left at room temperature for an extended period may have a compromised BUD even if the date on the label has not passed.

3. Documentation: Your clinic should document receipt dates, storage conditions, and administration dates for all compounded preparations. This creates an audit trail that demonstrates compliance.

Using a compounded preparation after its BUD has passed is a compliance violation. Under USP <797>, preparations past their BUD must be discarded. Administering a preparation past its BUD could also expose your clinic to liability if an adverse event occurs.

State boards of pharmacy and the FDA take BUD compliance seriously. During inspections, auditors will look at whether clinics are receiving, storing, and using compounded preparations within their labeled BUDs.

The pharmacy that compounds your GLP-1 preparations is responsible for assigning an appropriate BUD based on USP guidelines and any stability data they have generated. When evaluating a compounding partner, it is reasonable to ask:

• What BUD do you assign to your sterile GLP-1 preparations?
• Is that BUD based on default USP limits or extended stability testing?
• Do you have documentation of your stability testing available?
• Are your preparations compounded under Category 1 or Category 2 conditions?

A reputable 503B outsourcing facility will be able to answer these questions clearly and provide documentation. A 503A pharmacy operating under default USP limits will have shorter BUDs and should be transparent about that.

The 2023 revision to USP <797> significantly updated BUD requirements and introduced new sterility testing categories. Clinics and pharmacies that were operating under the 2008 version of USP <797> need to be aware that the rules have changed.

Key changes in the 2023 revision include:

• New Category 1 and Category 2 classification system replacing the old low/medium/high risk framework
• Updated BUD limits for each category
• New requirements for sterility testing, environmental monitoring, and personnel training
• Stricter documentation requirements

The FDA has indicated it will use the 2023 USP <797> standards as a reference in enforcement actions. Clinics and their pharmacy partners should be operating under the updated standards.

Understanding the BUD vs. expiration date distinction is not just academic — it has real operational implications:

• Always check the BUD on compounded preparations upon receipt and before administration
• Never use a preparation past its BUD, regardless of appearance or smell
• Store preparations as labeled — temperature excursions can invalidate a BUD even before the date passes
• Ask your pharmacy partner about their BUD assignment methodology and whether they conduct extended stability testing
• Document everything — receipt dates, storage logs, and administration records

Working with a pharmacy partner that operates under 503B outsourcing facility standards provides an additional layer of assurance. 503B facilities are subject to FDA inspection and must comply with cGMP standards, which include more rigorous stability and quality testing than typical 503A pharmacies.

1. United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. 2023 Revision.
2. United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. 2023 Revision.
3. U.S. Food and Drug Administration. Guidance for Industry: Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products. FDA, 2020.
4. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA, updated 2024.
5. 21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals.

MedClinic Partners connects licensed clinics and 503A pharmacies with vetted 503B supply and USA-made cGMP RUO peptides. Questions about compliance or supply? Use the Get Connected form to reach our team.